Cargando…

Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer

Detalles Bibliográficos
Autores principales:	Yochum, Zachary A., Stabile, Laura P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481617/ https://www.ncbi.nlm.nih.gov/pubmed/32953532 http://dx.doi.org/10.21037/tlcr-20-617

Ejemplares similares

Alternative splicing of HER2: a novel mediator of EGFR TKI resistance
por: Yochum, Zachary A., et al.
Publicado: (2020)

Parathyroid hormone assay: problems and opportunities
por: Martin, Kevin J., et al.
Publicado: (2007)

Challenges and Opportunities in Pharmacogenomics and Therapeutics
por: Kane, Michael D., et al.
Publicado: (2007)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer
por: Bennani-Baiti, Idriss M
Publicado: (2012)

Family medicine training in China: crisis and opportunity
por: Morikawa, Masahiro J
Publicado: (2020)

HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
por: Bardia, Aditya, et al.
Publicado: (2023)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

Obesity paradox and lung cancer, metformin-based therapeutic opportunity?
por: Barrios-Bernal, Pedro, et al.
Publicado: (2023)

CLOCK’ing differences in DNA methylation signatures to understand the molecular etiology of lung cancer
por: Neely, Aaron M., et al.
Publicado: (2023)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Race, ethnicity, and clinical outcomes in hormone receptor-positive, human epidermal growth factor 2 negative (HER2−), node negative breast cancer in the randomized TAILORx trial: gaps in biologic and social determinants of health
por: Beltran-Bless, Ana-Alicia, et al.
Publicado: (2022)

Antibiotic stewardship in neonates: challenges and opportunities
por: Ting, Joseph Y., et al.
Publicado: (2020)

Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities
por: Fu, Dongliao, et al.
Publicado: (2022)

Public Health Challenges in India: Seizing the Opportunities
por: Narain, Jai Prakash
Publicado: (2016)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Alteration of insulin sensitivity by sex hormones during the menstrual cycle
por: Sheu, Wayne H‐H
Publicado: (2011)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Chemotherapy in non-small cell lung cancer: opportunities for advancement
por: Akhtari, Mani, et al.
Publicado: (2016)

Multiparametric cystoscopy: opportunities to enhance bladder cancer detection
por: Taylor, Jacob, et al.
Publicado: (2020)

Community Pharmacy Response in the Aftermath of Natural Disasters: Time-Sensitive Opportunity for Research and Evaluation
por: Melin, Kyle, et al.
Publicado: (2018)

FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways
por: Rabik, Cara A., et al.
Publicado: (2020)

Gaps and opportunities: measuring the key population cascade through surveys and services to guide the HIV response
por: Hakim, Avi Joseph, et al.
Publicado: (2018)

Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Predicting response to HER2 kinase inhibition
por: Settleman, Jeff
Publicado: (2014)

The tRNA-derived fragment signature in lung cancer
por: Cingaram, Pradeep Reddy
Publicado: (2022)

EGFR Signaling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities
por: La Monica, Silvia
Publicado: (2022)

Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome()()
por: Siegfried, Jill M., et al.
Publicado: (2015)

Machine Learning in Health Care: A Critical Appraisal of Challenges and Opportunities
por: Sendak, Mark, et al.
Publicado: (2019)

Opportunities and Challenges of Delivering Postabortion Care and Postpartum Family Planning During the COVID-19 Pandemic
por: Pfitzer, Anne, et al.
Publicado: (2020)

Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung Cancer
por: Addeo, Raffaele
Publicado: (2021)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Pediatric COVID-19 Therapeutics: Seizing the Right Research and Development Opportunities to Accelerate Access for Children
por: Morin, Sébastien, et al.
Publicado: (2021)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

Corticotropin-Releasing Hormone: Biology and Therapeutic Opportunities
por: Caruso, Alessandra, et al.
Publicado: (2022)

Anesthesiologists in the modern medical school curriculum: importance and opportunity
por: Chuang, Zachary
Publicado: (2023)

How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?
por: Norton, Nadine, et al.
Publicado: (2013)

Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer
por: Ciliberto, Gennaro, et al.
Publicado: (2022)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

Family Physician Implementation and Preventive Medicine; Opportunities and Challenges
por: Majdzadeh, Reza
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l71no8vfd4kfsbefp2l8rn2024